Results 31 to 40 of about 2,343,487 (194)

CD63+ Cancer‐Associated Fibroblasts Confer Tamoxifen Resistance to Breast Cancer Cells through Exosomal miR‐22

Advanced Science, 2020
Tamoxifen remains the most effective treatment for estrogen receptor α (ERα)‐positive breast cancer. However, many patients still develop resistance to tamoxifen in association with metastatic recurrence, which presents a tremendous clinical challenge ...
Yuan Gao, Xiaoju Li, Cheng Zeng, Chenlin Liu, Qiang Hao, Weina Li, Kuo Zhang, Wangqian Zhang, Shuning Wang, Huadong Zhao, Dong Fan, Meng Li, Yingqi Zhang, Wei Zhang, Cun Zhang   +14 more
doaj   +1 more source

Prior Adjuvant Tamoxifen Treatment in Breast Cancer Is Linked to Increased AIB1 and HER2 Expression in Metachronous Contralateral Breast Cancer.

PLoS ONE, 2016
AimThe estrogen receptor coactivator Amplified in Breast Cancer 1 (AIB1) has been associated with an improved response to adjuvant tamoxifen in breast cancer, but also with endocrine treatment resistance.
Sara Alkner, Pär-Ola Bendahl, Anna Ehinger, Kristina Lövgren, Lisa Rydén, Mårten Fernö   +5 more
doaj   +1 more source

Partial depletion of plasminogen activator inhibitor‐1 decreases subcutaneous fat cell hypertrophy and liver cholesterol in high‐fat‐fed female mice

FEBS Letters, EarlyView.
Obesity raises blood levels of PAI‐1, a protein linked to metabolic dysfunction‐associated steatotic liver disease in people with obesity. In female mice fed a high‐fat diet, partially lowering PAI‐1 led to smaller subcutaneous fat cells and lower liver cholesterol, without changing body weight or insulin sensitivity.
Claudia E. Ramirez Bustamante, Robert Sharp, Pradip K. Saha, Elizabeth S. Anaya, Elizabeth L. Lieu, Evelyn L. de Groot, Pooja Patel, Mi Jeong Heo, Aaron R. Cox, Kang Ho Kim, Sean M. Hartig   +10 more
wiley   +1 more source

Expression of HIF-1α is related to a poor prognosis and tamoxifen resistance in contralateral breast cancer.

PLoS ONE, 2019
BACKGROUND:Adjuvant endocrine treatment improves survival after estrogen receptor (ER) positive breast cancer. Recurrences occur, and most patients with metastatic breast cancer develop treatment resistance and incurable disease. An influential factor in
Annika Jögi, Anna Ehinger, Linda Hartman, Sara Alkner   +3 more
doaj   +1 more source

MTDH Mediates Estrogen-Independent Growth and Tamoxifen Resistance by Down-Regulating PTEN in MCF-7 Breast Cancer Cells

Cellular Physiology and Biochemistry, 2014
Background: About 70% of human breast cancers express estrogen receptor α (ERα) and in this kind of breast cancer estrogen plays an important role. Estrogen independent growth has been reported to promote resistance to one of the selective estrogen ...
Chunyuan Xu, Xiaoli Kong, Haiji Wang, Ning Zhang, Xiangnan Kong, Xia Ding, Xiaoyan Li, Qifeng Yang   +7 more
doaj   +1 more source

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancer [PDF]

, 2010
Tamoxifen is the most widely prescribed anti-estrogen treatment for patients with estrogen receptor (ER)-positive breast cancer. However, there is still a need for biomarkers that reliably predict endocrine sensitivity in breast cancers and these may ...
Liang, Liang, J Michael Dixon, Muir, Morwenna, David A Cameron, Walker, Graeme, Sims, Andrew H., Morwenna Muir, Liang Liang, Muir, Morwenna; id_orcid, Langdon, Simon P., Dixon, J. Michael, Sims, Andrew, Taylor, Karen J., Dana Faratian, Graeme Walker, Cameron, David A., Simon P Langdon, Dixon, Mike, Karen J Taylor, Taylor, Karen J, Harrison, David J, Barbara Kuske, David J Harrison, Cameron, David A, Faratian, Dana, Kuske, Barbara, Andrew H Sims, Langdon, Simon P, Harrison, David J., Harrison, David J.; id_orcid   +29 more
core   +2 more sources

Spatial and single‐nuclei transcriptomics reveals idiosyncratic and generic patterns in papillary and anaplastic thyroid cancers

Molecular Oncology, EarlyView.
Matched spatial transcriptomics and single‐nuclei RNA‐seq were generated for anaplastic and BRAFV600E papillary thyroid cancers revealing generic and tumor‐specific states occurring in cancer cells and in the tumor microenvironment. In this context, cancer dedifferentiation mirrored organoid maturation through ordered thyroid marker gain/loss ...
Adrien Tourneur, Joel Rodrigues Vitória, Manuel Saiselet, Ligia Craciun, Denis Larsimont, Anne Lefort, Frédérick Libert, Carine Maenhaut, Sabine Costagliola, Maxime Tarabichi, Mirian Romitti, Vincent Detours   +11 more
wiley   +1 more source

Estrogen receptor co-regulators as prognostic and predictive markers of endocrine therapy in early breast cancer: the role of SMRT and p160 family [PDF]

, 2010
Background: The estrogen receptor (ER) signaling pathway is the dominant driver of cell proliferation and survival in the majority of human breast cancers.
Migliaccio, Ilenia
core   +1 more source

HOXA5 confers tamoxifen resistance via the PI3K/AKT signaling pathway in ER-positive breast cancer [PDF]

, 2021
Tamoxifen is a commonly used drug to treat estrogen receptor-positive patients with breast cancer. Despite the outstanding efficacy of tamoxifen, approximately one-third of patients develop resistance toward it, thereby presenting a therapeutic challenge.
김명희, 김유리, 오지훈, Myoung Hee Kim, Clara Yuri Kim, Ji Hoon Oh, Yu Cheon Kim   +6 more
core   +1 more source